Application Note: Rapid High-Resolution Screening of Plasma B Cells to Identify Antibody Lead Candidates
Explore case studies for the rapid discovery of antibodies against challenging targets.
BROCHURE: Cell Therapy Development
From expanding rare, antigen-specific T cells to fully characterizing them, learn how our capabilities are making cell therapy development more efficient.
Customer Spotlight: Abveris on Antibody Discovery
Find out how Abveris is transforming their antibody discovery processes with the Beacon® optofluidic system.
BROCHURE: Beacon® Optofluidic System
Discover how the Beacon system shortens timelines, simplifies workflows and reveals detailed data through deep profiling.
Application Note: Multidimensional Analysis of T Cell Cytotoxicity and Serial Killing Using the Opto™ Cell Therapy Development Workflow
Learn how to use multiple assays on single T cells to finally understand critical functions, such as serial killing, and how they relate to each other.
Application Note: Identify and Select Optimal CAR T Cell Phenotypes with the Opto™ Cell Therapy Development Workflow
Learn how to combine the T Cell Proliferation Assay with either the Multiplex Cytokine Assay or Cytotoxicity Assay to find your most persistent T cells.
Customer Spotlight: Amgen on AbD and CLD
Find out how Amgen is transforming their antibody discovery and clonal cell line processes with the Berkeley Lights Platform.
Fireside Chat: Every Day Matters – Optimizing COVID-19 Therapies for Manufacturing
Dr. James Rothman, Nobel Laureate hosts an in-depth discussion with distinguished guests, Dr. Jennitte Stevens from Amgen, Dr. Gregory Bleck from Catalent-Biologics, and Dr. Trent Munro from the University of Queensland on fast-tracking the development of therapeutic antibodies and vaccines for SARS-CoV-2.
Webinar: Expand and Rapidly Validate Antigen-Specific Function of T Cells Using Fewer Cells
Yelena Bronevetsky, PhD, lays out the current challenges in tumor antigen discovery and how our Opto™ Antigen Presenting Bead Kit helps scientists overcome them.
Application Note: Rapid Discovery of Therapeutic Antibodies for the SARS-CoV-2 Pandemic Virus Using the Opto Viral Neutralization 1.0 Workflow
Learn how to use blocking and binding assays and the Opto Viral Neutralization 1.0 workflow to identify cross-reactive antibodies that may have broad neutralization capacity across the coronavirus family.
Customer Spotlight: Catalent on CLD
Find out how Catalent Biologics is able to select significantly higher expressing clonal cell lines with the Opto CLD workflow.
Product Tour: The Opto™ Cell Therapy Development Workflow
Guided by T cell expert, Yelena Bronevetsky, PhD, get a deeper look at how the Opto™ Cell Therapy Development workflow can be used to validate, expand, and fully characterize over a 1,000 T cells.
Brochure: Lightning System
Find out how the Lightning platform lets you visualize diverse cell interactions, measure individual cell cytotoxicity, and recover cells of interest alive.
Webinar: Rapid Discovery of a Diverse Panel of Antibodies Against Membrane Targets Using the Beacon System
Dr. Shireen Khan presents a case study on how ChemPartner has leveraged the Beacon system to rapidly discover cross-reactive antibodies against the GPI-anchored uPA receptor.
Webinar: Rapid Discovery of Functional Antibodies for SARS-CoV-2 Using the Beacon System
Robert Carnahan, PhD, and Seth Zost, PhD, from the Vanderbilt University Medical Center, describe how they have used the Beacon platform, to rapidly discover hundreds of unique antibodies against SARS-CoV-2.
SynBioBeta Live Roundtable: Can Humanity Build a Global Antibody Defense Barrier Against Future Pandemics?
Listen to the world’s leading experts on antibody discovery to discuss how we can build a global defensive barrier to find new therapeutic antibodies against the coronavirus and future pathogens.
Datasheet: Cell Analysis Suite (CAS™) 2.1 Software
Review our premier software, its key applications, and the features exclusive to the 2.1 upgrade.
Webinar: How Pediatric Immune Systems Empower Cancer Immunotherapy
Dr. David Barrett shares insights into why children’s T cells help CAR-T cells succeed and discusses how the Opto Cell Therapy Development Workflow can provide the detailed characterization required to develop more efficacious therapies.